Skip to main content
Erschienen in: Rheumatology International 1/2022

15.01.2021 | Observational Research

Performance of diagnostic criteria in pediatric Behçet’s disease

verfasst von: Tuba Kurt, Fatma Aydın, Müge Sezer, P. Nilüfer Tekgöz, Zahide Ekici Tekin, Elif Çelikel, Cüneyt Karagöl, Serkan Coşkun, Banu Acar

Erschienen in: Rheumatology International | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Behçet's disease is an inflammatory vasculitic disease of unknown etiology characterized by recurrent oral and genital ulcers, ocular findings, and multiple organ involvement. Mucocutaneous findings are the most common symptoms. The most used diagnostic criteria are International Criteria for BD (ICBD), International Study Group (ISG) criteria and pediatric Behçet’s disease criteria (PEDBD). Although diagnostic criteria have been defined, the diagnosis is still difficult due to clinical findings developed in pediatric patients. The aim of this study was to evaluate the clinical findings, phenotype characteristics, sensitivity and specificity of diagnostic criteria, and the course of pediatric Behçet's disease (BD). We evaluated retrospectively the files of 67 (29 M/38 F) patients diagnosed with BD according to expert opinion. The patients were reclassified according to ISG, ICBD, and PEDBD criteria. The control group consisted of a total of 69 patients with BD-mimicking diseases or presenting at least one major BD sign followed at the same center. Sensitivity and specificity were evaluated for the criteria. The mean age of diagnosis was 13.38 ± 3.2 years. There were oral aphthous ulcers in 98.5%, genital ulcers in 68.7%, skin lesions in 31.3%, vascular involvement in 17.9%, neurological involvement in 11.9%, positive pathergy test in 33.8%, and positive HLA-B51 in 57.1% of patients. The sensitivity of ICBD, ISG and PEDBD criteria was 88.1, 43.3, and 37.3%, respectively. The specificity of ICBD, ISG, and PEDBD criteria was 100%. Diagnosis of BD in childhood is still difficult. ICBD criteria have the highest sensitivity among the diagnostic criteria. These criteria can also be used in childhood.
Literatur
1.
Zurück zum Zitat Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2019) One year in review 2019: Behçet’s syndrome. Clin Exp Rheumatol 37(Suppl 121):3–17PubMed Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2019) One year in review 2019: Behçet’s syndrome. Clin Exp Rheumatol 37(Suppl 121):3–17PubMed
2.
Zurück zum Zitat Shahram F, Nadji A, Akhlaghi M, Faezi ST, Chams-Davatchi C, Shams H et al (2018) Pediatric Behçet’s disease in Iran: report of 204 cases. Clin Exp Rheumatol 36(6 Suppl 115):135–140PubMed Shahram F, Nadji A, Akhlaghi M, Faezi ST, Chams-Davatchi C, Shams H et al (2018) Pediatric Behçet’s disease in Iran: report of 204 cases. Clin Exp Rheumatol 36(6 Suppl 115):135–140PubMed
3.
Zurück zum Zitat Ishido T, Horita N, Takeuchi M, Kawagoe T, Shibuya E, Yamane T et al (2017) Clinical manifestations of Behçet’s disease depending on sex and age: results from Japanese nationwide registration. Rheumatology (Oxford) 56(11):1918–1927CrossRef Ishido T, Horita N, Takeuchi M, Kawagoe T, Shibuya E, Yamane T et al (2017) Clinical manifestations of Behçet’s disease depending on sex and age: results from Japanese nationwide registration. Rheumatology (Oxford) 56(11):1918–1927CrossRef
4.
Zurück zum Zitat Karincaoglu Y, Borlu M, Toker SC, Akman A, Onder M, Gunastı S et al (2008) Demographic and clinical properties of juvenile-onset Behçet’s disease: a controlled multicenter study. J Am Acad Dermatol 58(4):579–584CrossRef Karincaoglu Y, Borlu M, Toker SC, Akman A, Onder M, Gunastı S et al (2008) Demographic and clinical properties of juvenile-onset Behçet’s disease: a controlled multicenter study. J Am Acad Dermatol 58(4):579–584CrossRef
5.
Zurück zum Zitat Rodríguez-Carballeira M, Solans R, Larrañaga JR, García-Hernández FJ, Rios-Fernández R, Nieto J et al (2018) Venous thrombosis, and relapses in patients with Behçet’s disease. Descriptive analysis from Spanish network of Behçet’s disease (REGEB cohort). Clin Exp Rheumatol. 36(6 Suppl):40–44PubMed Rodríguez-Carballeira M, Solans R, Larrañaga JR, García-Hernández FJ, Rios-Fernández R, Nieto J et al (2018) Venous thrombosis, and relapses in patients with Behçet’s disease. Descriptive analysis from Spanish network of Behçet’s disease (REGEB cohort). Clin Exp Rheumatol. 36(6 Suppl):40–44PubMed
6.
Zurück zum Zitat Maldini C et al (2018) Exploring the variability in Behcet’s disease prevalence: a metaanalytical approach. Rheumatology (Oxford) 57(1):185–195CrossRef Maldini C et al (2018) Exploring the variability in Behcet’s disease prevalence: a metaanalytical approach. Rheumatology (Oxford) 57(1):185–195CrossRef
8.
Zurück zum Zitat Akkoç N (2018) Update on the epidemiology, risk factors and disease outcomes of Behçet’s disease. Best Pract Res Clin Rheumatol 32(2):261–270CrossRef Akkoç N (2018) Update on the epidemiology, risk factors and disease outcomes of Behçet’s disease. Best Pract Res Clin Rheumatol 32(2):261–270CrossRef
9.
Zurück zum Zitat Davatchi F, Sadeghi Abdollahi B, Chams-Davatchi C, Shahram F, Shams H, Nadji A et al (2015) The saga of diagnostic/classification criteria in Behcet’s disease. Int J Rheum Dis 18(6):594–605CrossRef Davatchi F, Sadeghi Abdollahi B, Chams-Davatchi C, Shahram F, Shams H, Nadji A et al (2015) The saga of diagnostic/classification criteria in Behcet’s disease. Int J Rheum Dis 18(6):594–605CrossRef
10.
Zurück zum Zitat Criteria for diagnosis of Behçet’s disease (1990) International Study Group for Behçet’s disease. Lancet 335(8697):1078–1080 Criteria for diagnosis of Behçet’s disease (1990) International Study Group for Behçet’s disease. Lancet 335(8697):1078–1080
11.
Zurück zum Zitat International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD) (2014) The International Criteria for Behçet’s Disease ICBD: a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347CrossRef International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD) (2014) The International Criteria for Behçet’s Disease ICBD: a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347CrossRef
12.
Zurück zum Zitat Kone-Paut I et al (2016) Consensus classification criteria for pediatric Behcet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis 75(6):958–964CrossRef Kone-Paut I et al (2016) Consensus classification criteria for pediatric Behcet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis 75(6):958–964CrossRef
13.
Zurück zum Zitat Krause I, Uziel Y, Guedj D et al (1999) Childhood Behcet’s disease: clinical features and comparison with adult-onset disease. Rheumatology 38(5):457–462CrossRef Krause I, Uziel Y, Guedj D et al (1999) Childhood Behcet’s disease: clinical features and comparison with adult-onset disease. Rheumatology 38(5):457–462CrossRef
14.
Zurück zum Zitat Batu ED, Sönmez HE, Sözeri B, Butbul Aviel Y, Bilginer Y, Özen S (2017) The performance of different classification criteria in pediatric Behcet’s disease. Clin Exp Rheumatol 35(Suppl 108):119–123PubMed Batu ED, Sönmez HE, Sözeri B, Butbul Aviel Y, Bilginer Y, Özen S (2017) The performance of different classification criteria in pediatric Behcet’s disease. Clin Exp Rheumatol 35(Suppl 108):119–123PubMed
15.
Zurück zum Zitat Gallizzi R et al (2017) A national cohort study on pediatric Behcet’s disease: cross sectional data from an Italian registry. Pediatr Rheumatol Online J 15(1):84CrossRef Gallizzi R et al (2017) A national cohort study on pediatric Behcet’s disease: cross sectional data from an Italian registry. Pediatr Rheumatol Online J 15(1):84CrossRef
16.
Zurück zum Zitat Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A (2012) Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 51(5):887–900CrossRef Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A (2012) Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 51(5):887–900CrossRef
17.
Zurück zum Zitat Ambrose NL, Haskard DO (2013) Differential diagnosis and management of Behçet syndrome. Nat Rev Rheumatol 9(2):79–89CrossRef Ambrose NL, Haskard DO (2013) Differential diagnosis and management of Behçet syndrome. Nat Rev Rheumatol 9(2):79–89CrossRef
18.
Zurück zum Zitat Kang EH, Kim JY, Takeuchi F, Kim JW, Shin K, Lee EY et al (2011) Associations between the HLA-A polymorphism and the clinical manifestations of Behcet’s disease. Arthritis Res Ther 13(2):R49CrossRef Kang EH, Kim JY, Takeuchi F, Kim JW, Shin K, Lee EY et al (2011) Associations between the HLA-A polymorphism and the clinical manifestations of Behcet’s disease. Arthritis Res Ther 13(2):R49CrossRef
Metadaten
Titel
Performance of diagnostic criteria in pediatric Behçet’s disease
verfasst von
Tuba Kurt
Fatma Aydın
Müge Sezer
P. Nilüfer Tekgöz
Zahide Ekici Tekin
Elif Çelikel
Cüneyt Karagöl
Serkan Coşkun
Banu Acar
Publikationsdatum
15.01.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 1/2022
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04777-0

Weitere Artikel der Ausgabe 1/2022

Rheumatology International 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.